
Vivesto Investor Relations Material
Latest events

R&D Update
Vivesto
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Vivesto
Access all reports
Segment Data
Access more data
Net sales by
Source
Sales of goods
Expenses by
Financials
Vivesto AB develops, manufactures, markets, and sells drugs in the field of human and veterinary oncology primarily in Sweden. The company offers XRP988/Apealea/Doxophos that is a drug consisting of doxorubicin encapsulated in an oil-based carrier system for injection; and Paclical/Apalutamide that is an oral formulation of a pure antiandrogen. It serves various markets through third party distributors. The company was formerly known as Oasmia Pharmaceutical AB and changed its name to Vivesto AB in March 2022. The company was founded in 1988 and is headquartered in Solna, Sweden.
Latest articles
)
Lowe's Companies: Building a One-Stop Shop for Home Improvement
Lowe's Companies began as a single store in 1921 and has steadily expanded its footprint and offerings, now operating 1,750 stores across the U.S.
7 May 2025
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
)
Intuitive Surgical: Enhancing Surgery with Robotic Precision
Intuitive Surgical has revolutionized surgery with robotics, building its dominant position through decades of innovation, validation, and expansion.
2 May 2025
Ticker symbol
VIVE
Country
🇸🇪 Sweden